<DOC>
	<DOCNO>NCT01288716</DOCNO>
	<brief_summary>To explore efficacy , safety tolerability STX209 ( arbaclofen ) administer treatment social withdrawal subject autism spectrum disorder</brief_summary>
	<brief_title>Study Arbaclofen Treatment Social Withdrawal Subjects With Autism Spectrum Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<criteria>Diagnosis Autism Spectrum Disorders ( ASD ) Current pharmacological treatment regimen stable least 4 week prior Screening . Subjects history seizure disorder must currently receive treatment antiepileptic must seizure free 6 month , must seizure free 3 year currently receive antiepileptic . If subject already receive stable nonpharmacologic educational , behavioral , and/or dietary intervention , participation program must continuous 2 month prior Screening Subjects condition , include alcohol drug abuse , might interfere conduct study , confound interpretation study result , endanger wellbeing . Subjects plan initiate change pharmacologic nonpharmacologic intervention course study . Subjects take another investigational drug within last 30 day . Subjects able take oral medication</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>ASD</keyword>
	<keyword>Autism</keyword>
	<keyword>Asperger Syndrome</keyword>
</DOC>